跳至主要内容
临床试验/NCT01402596
NCT01402596撤回2 期

Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam - a Randomized Controlled Trial

University of Sao Paulo1 个研究点 分布在 1 个国家开始时间: 2011年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
试验地点
1
主要终点
Adverse Events

研究概览

简要总结

Thousands of children receive sedation for diagnostic and therapeutic interventions annually, and this number is expected to increase. Children are at higher risk for sedation-related complications than adults. In different scenarios, multiple drugs are used to achieve sedation, each one with particular adverse events that must be monitored and reported.

Children that need CT scans for traumatic brain injuries often need sedation, without needing and IV line for that. Chloral hydrate is an hypnotic agent used since 1832 with low incidence of adverse events; however, despite its worldwide use, it's being abandoned due to bitter taste, long time of sedation onset, vomiting and mild sedation. Intranasal midazolam, on the other hand, produces high and fast concentrations on CSF with greater rates of success but probably with higher adverse events. There are no prospective studies with large series of patients using intranasal midazolam.

The aim of this study is to determine if nasal midazolam is a safer approach and more effective sedative regimen when compared to rectal chloral hydrate to children undergoing CT scans.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Month 至 3 Years(Child)
性别
All
接受健康志愿者

入选标准

  • children undergoing CT scanning for TBI

排除标准

  • epistaxis
  • suspected or confirmed skull or nasal fracture
  • Moderate to severe traumatic brain injury
  • hemodynamically unstable

研究组 & 干预措施

Chloral hydrate

Active Comparator

Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.

干预措施: Chloral Hydrate (Drug)

Midazolam

Active Comparator

Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.

干预措施: Midazolam (Drug)

结局指标

主要结局

Adverse Events

时间窗: Participants will be followed for the duration of hospital (emergency department) stay, an expected average of 2-3 hours

Such as hypoxemia, respiratory depression, vomiting, hypotension

次要结局

  • Efficacy of both drugs(Participants will be followed for the duration of hospital (emergency department) stay, an expected average of 2-3 hours)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验